L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni riguardanti il rischio di esiti avversi della gravidanza
correlato ai farmaci contenenti valproato (sodio valproato, magnesio
valproato, acido valproico, semisodio valproato e valpromide), a seguito
del completamento di una revisione a livello europeo.
May result in a delay in therapy.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni relative al rischio di insorgenza di leucoencefalopatia multifocale progressiva (PML) correlata all’uso di Tecfidera nel trattamento della sclerosi multipla.
Using these recalled devices may cause ineffective patient treatment.
May result in a delay in therapy.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Symptoms of PML may include: progressive weakness on one side of the body or clumsiness of limbs; disturbance of vision; and changes in thinking, memory and orientation. The progression of deficits can lead to severe disability or death.
Sildenafil may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke.
80.211.154.110
